Moleculin Biotech, Inc., (NASDAQ: MBRX) shares hav
Post# of 23078
(Total Views: 208)
Posted On: 06/29/2017 6:47:47 AM
Moleculin Biotech, Inc., (NASDAQ: MBRX) shares have soared this latest week, closing Tuesday up 66% to $3.28. Just last week the stock was trading at a mere $0.81. The company will host a conference call on Thursday, June 29, 2017 at 4:30 PM ET to discuss what it refers to as “the recent new discovery of a metabolic inhibitor with the potential to treat pancreatic cancer as well as to provide a business update.” The company will no doubt be hoping to keep its stock price above $1.00 for ten consecutive days to regain compliance with NASDAQ’s Bid Price Rule.
Janssen Research & Development (JNJ) announced that the FDA has assigned a PDUFA date under priority review of October 28, 2017 for the supplemental New Drug Application (sNDA) of XARELTO (rivaroxaban) to include a 10 mg once-daily dose for reducing the risk of VTE after at least six months of standard anticoagulant therapy.
Akebia Therapeutics, Inc. (NASDAQ:AKBA) announced the pricing of an underwritten public offering of 4,000,000 shares at a price of $14.50 per share. Shares closed the after-hours session down 4.7% to $14.78.
Gemphire Therapeutics Inc.(NASDAQ:GEMP) announced that it met the primary endpoint from its Phase 2b COBALT-1 trial. COBALT-1 evaluated gemcabene in homozygous familial hypercholesterolemia (HoFH) patients who are on stable maximally tolerated lipid-lowering therapies to assess the efficacy, safety, and tolerability of multiple rising doses of gemcabene. Gemcabene 300 mg lowered LDL-C by a mean of 25% (p=0.0063; range -55% to +1%), while the 600mg and 900mg doses lowered LDL-C by a mean of 30% (p=0.0047) and 29% (p=0.0035), respectively. Shares closed the after-hours session up 10% to $13.50.
Major price movers (stocks priced > $1.00, volume > 100k):
ADVANCERS:
Cascadian Therapeutics Inc (NASDAQ:CASC): $4.26; +18%.
DelMar Pharmaceuticals Inc (NASDAQ
MPI): $2.36; +17%.
Ra Pharmaceuticals Inc (NASDAQ:RARX): $19.88; +12%.
Fibrocell Science Inc (NASDAQ:FCSC): $4.31; +10%.
Merrimack Pharmaceuticals Inc (NASDAQ:MACK): $1.40; +10%.
DECLINERS:
Flex Pharma Inc (NASDAQ:FLKS): $3.82; -10%.
Alder Biopharmaceuticals Inc (NASDAQ:ALDR): $12.15; -10%.
Omeros Corporation (NASDAQ:OMER): $20.34; -9%.
Matinas BioPharma Holdings Inc (NYSEMKT:MTNB): $1.67; -8%.
Minerva Neurosciences Inc (NASDAQ:NERV): $7.95; -8
Janssen Research & Development (JNJ) announced that the FDA has assigned a PDUFA date under priority review of October 28, 2017 for the supplemental New Drug Application (sNDA) of XARELTO (rivaroxaban) to include a 10 mg once-daily dose for reducing the risk of VTE after at least six months of standard anticoagulant therapy.
Akebia Therapeutics, Inc. (NASDAQ:AKBA) announced the pricing of an underwritten public offering of 4,000,000 shares at a price of $14.50 per share. Shares closed the after-hours session down 4.7% to $14.78.
Gemphire Therapeutics Inc.(NASDAQ:GEMP) announced that it met the primary endpoint from its Phase 2b COBALT-1 trial. COBALT-1 evaluated gemcabene in homozygous familial hypercholesterolemia (HoFH) patients who are on stable maximally tolerated lipid-lowering therapies to assess the efficacy, safety, and tolerability of multiple rising doses of gemcabene. Gemcabene 300 mg lowered LDL-C by a mean of 25% (p=0.0063; range -55% to +1%), while the 600mg and 900mg doses lowered LDL-C by a mean of 30% (p=0.0047) and 29% (p=0.0035), respectively. Shares closed the after-hours session up 10% to $13.50.
Major price movers (stocks priced > $1.00, volume > 100k):
ADVANCERS:
Cascadian Therapeutics Inc (NASDAQ:CASC): $4.26; +18%.
DelMar Pharmaceuticals Inc (NASDAQ
MPI): $2.36; +17%. Ra Pharmaceuticals Inc (NASDAQ:RARX): $19.88; +12%.
Fibrocell Science Inc (NASDAQ:FCSC): $4.31; +10%.
Merrimack Pharmaceuticals Inc (NASDAQ:MACK): $1.40; +10%.
DECLINERS:
Flex Pharma Inc (NASDAQ:FLKS): $3.82; -10%.
Alder Biopharmaceuticals Inc (NASDAQ:ALDR): $12.15; -10%.
Omeros Corporation (NASDAQ:OMER): $20.34; -9%.
Matinas BioPharma Holdings Inc (NYSEMKT:MTNB): $1.67; -8%.
Minerva Neurosciences Inc (NASDAQ:NERV): $7.95; -8
(1)
(0)
'Everything works out in the end,,,If it hasn't worked out,,it's not the end'
https://twitter.com/twitter/statuses/957208055766241280
https://twitter.com/twitter/statuses/957208055766241280